Profile cover photo
Profile photo
Centre for the Study of the Economies of Africa
The Centre for the Study of the Economies of Africa (CSEA) is an independent non-profit research organization established in April 2008
The Centre for the Study of the Economies of Africa (CSEA) is an independent non-profit research organization established in April 2008


Post has attachment
 CSEA Launches new website on 27th November 2014.

The Centre for the Study of the Economies of Africa (CSEA) is delighted to share with you its newly redesigned website, with a bold new look and enhanced navigation experience.

The new design is user-friendly and has been crafted to provide easy access to the information you need at any time of the day. The website now features an online store for Policy-oriented Research and Reports. 

To visit our new website do use the link
Add a comment...

#CSEA#Nigeria Economic Review#

A bi-annual report to keep you informed about the economy.

The Centre for the Study of the Economies of Africa (CSEA) presents the maiden edition of the Nigeria Economic Review. The report features findings and discussion on Global Economic Performance, Macroeconomic Performance, Energy Sector Performance, Domestic Sectoral Performance in the first half and an outlook for the second half of 2014.


Globally, advanced economies showed strong signs of recovery during the first half of 2014 while economic activities slowed and growth was below projection in emerging and developing economies.

Total federally collected revenue increased to N2.42 trillion in 2014 first quarter compared to N2.20 trillion in 2013 fourth quarter as a result of a significant increase in crude oil and gas exports to some countries like India, Malaysia and China.

To request a copy of the Report, send an email to
Add a comment...

Trade, Investment and Growth (TIG)

The Trade, Investment and Growth (TIG) research area examines regional integration and intra-regional trade in Africa, with emphasis on their effects on inclusive growth and poverty reduction. It also investigates the determinants and impacts of FDI in Africa and tracks the economic competitiveness of countries in the region. The specific thematic issues to be examined are as follows.

Regional Integration and Intra-Regional Trade

Around the world, there has been an increasing proliferation of regional trade agreements (RTAs) in their different forms, ranging from preferential trade agreements (PTAs) to economic and monetary unions (EMUs). Among other things, RTAs have been noted to provide the opportunity for deepened intra-regional trade, enhanced competitiveness, generation of growth spillovers, increased bargaining power on the multilateral front, and conflict prevention and resolution. Thus, the effects of RTAs in Africa are worthy of investigation.

Use the link to read full report
Add a comment...

Post has attachment
Education, Health and Population Dynamics (EHPD)

The Education, Health and Population Dynamics (EHPD) program is the anchor of CSEA’s activities in the areas of human capital development, labor markets and urbanization. EHPD comprises five research components that focus on the following policy issues.

Learning Achievement

After a long period of focusing on school enrolment, policymakers are shifting attention to the quality of education received in institutions of learning, from primary through tertiary levels, and on strategies to improve learning achievement. CSEA’s research focuses on the relationship between school quality and learning outcomes, with a view to enhancing the impact of educational policies.

Click link for full report
Add a comment...

#CSEA#Raising the awareness on Ebola Virus.

Twenty(20) Facts you should know about the disease

Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans.

Ebola virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.

In Africa, Ebola infection has been documented through the handling of infected fruit bats, monkeys or forest antelope

The countries at the centre of the Ebola outbreak are Guinea, Liberia and Sierra Leone

According to World Health Organisation (WHO), the current outbreak has had a survival rate of about 40%

Ebola spreads through bodily contact with the blood, secretions or other bodily fluids of infected animals or persons, dead or alive

Health-care workers have frequently been infected while treating patients with suspected or confirmed Ebola.

Ebola symptoms include sudden onset of fever, intense weakness, muscle pain, headache and sore throat.

Other symptoms include vomiting, diarrhea, rash, impaired kidney and liver function and internal and external bleeding.

People are infectious as long as their blood and secretions contain the virus. The incubation period from infection with the virus to onset of symptoms, is 2 to 21 days.

No licensed vaccine for Ebola is available. Several vaccines are being tested, but none are available for clinical use.

If an Ebola outbreak is suspected, the premises should be quarantined immediately.

Severely ill patients require intensive supportive care as patients are frequently dehydrated and require oral rehydration with solutions containing electrolytes or intravenous fluids.

An active animal health surveillance system to detect new cases is essential in providing early warning for veterinary and human public health authorities.

In the absence of effective treatment and a human vaccine, raise awareness of the risk factors for Ebola infection

Avoid infected fruit bats or monkeys and the consumption of their raw meat. Animals should be handled with gloves and cooked well before consumption.

Close physical contact with Ebola patients should be avoided, wear proper protective equipment if you must.

Regular hand washing is required after visiting patients in hospital, as well as after taking care of patients at home.

People who have died from Ebola should be promptly and safely buried.

Health-care workers caring for patients with suspected or confirmed Ebola virus should apply all standard precautions.
Add a comment...

#CSEA#Here is a little summary on Intermediate Good Trade in ECOWAS  (paper by Dr. Chuka & Idris)

The paper examines trade in intermediate goods in the ECOWAS region (both within itself and with the rest of the world) focusing on its drivers and how well the popular gravity model performs in explaining the pattern.
Add a comment...

Post has attachment
#CSEA#Working Paper WPS/14/02

Explaining Sectoral and Spatial Variations in Growth Pro-poorness in Nigeria.
By: Dr. Ebere Uneze and Adedeji Adeniran.

Click link to view complete report
Add a comment...

Ongoing Ebola outbreak sparks debate on experimental vaccine testing
By Emily Matty Mullins

International debate is brewing over whether to give experimental vaccines to people in regions of the current Ebola outbreak in West Africa as part of an effort to thwart the deadly virus' spread.

Despite the severity of the disease, which causes hemorrhagic fever and kills up to 90% of its victims, some experts are urging against using experimental vaccines for safety reasons. There are no approved drugs to treat Ebola.

Dr. David Heymann, a professor of infectious diseases at the London School of Hygiene and Tropical Medicine and former assistant director at the WHO, told the Ottawa Citizen that it would be "unethical" to roll out experimental vaccines in at-risk populations in Africa now. Heymann was a member of the team that responded to the first Ebola outbreak in 1976.

One of the Ebola therapies in development--Tekmira Pharmaceuticals' ($TKMR) RNA interference therapeutic, which is intended to work by "silencing" disease-causing genes--has been placed on clinical hold by the FDA over safety concerns.

Tekmira's investigational drug is an RNAi therapeutic, not a vaccine. However, the few Ebola vaccines that in development are still in very early stages. Currently, Inovio Pharmaceuticals ($INO) and Vaxart are testing Ebola vaccines in animals, and last year GlaxoSmithKline ($GSK) acquired Swiss biotech Okairos, which has an Ebola vaccine in the preclinical phase.

The challenge with drug development for Ebola is the relatively low incentive for biotech and pharma companies. The virus is still rare, and has yet to spread outside Africa, although outbreaks have been increasing in frequency since Ebola was discovered in 1976.
Add a comment...

#CSEA# Here is a little summary on Job Creation and Employment Generation in Nigeria: Some Policy Choices (Paper by OT and Ola)

The paper provides a succinct analysis of the unemployment challenge and assesses the growth-employment nexus in Nigeria, based on analysis of sectoral production functions. In addition, it analyzes the labor market from a microeconomic perspective and provides policy analysis of policy options.
Add a comment...

Here is a brief summary on: Macroeconomic Determinants of Banking Performance in ECOWAS: An Econometric Investigation.

The services sector is the main driver of most economies in the region, and the financial services sector plays an important role in the process. The study investigates the macroeconomic determinants of banking performance in ECOWAS given that the banking sector is the major conduit through which macroeconomic shocks are transmited to the economy.
Add a comment...
Wait while more posts are being loaded